Previous Close | 89.22 |
1-Year Change | 0% |
6-Months Change | -6.8% |
3-Months Change | 19.2% |
Moving Avg (50d) | 77.548 |
Moving Avg (200d) | 81.782 |
ESG Rating | - |
Exchange | NYSE |
Market Cap. | 4.53B |
Beta (3-Years) | 0.81 |
Revenue Growth (ttm) | 49.97% |
Net Profit Margin (ttm) | 10.35% |
Return On Assets (ttm) | 6.38% |
EPS (ttm) | 2.49 |
PE Ratio (ttm) | 35.83 |
Dividend Yield | % |
Asset Description: | Haemonetics Corporation |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2024-10-29 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
87.261 | 89.828 | 91.539 | 94.105 | 98.383 | 102.66 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Health Care Supplies |
Country: | United States |
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen Latham in the 1970s. Today, the company has expanded and has offices located in 16 countries. The company employs more than 1,800 people and markets its products in over 50 countries. Revenue is derived nearly equally from its three major markets -- Asia,... Wikipedia